This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Quadrivalent (ACWY) polysaccharide meningococcal C vaccine

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

quadrivalent (ACWY) polysaccharide vaccine

  • this polysaccharide (non-conjugated) vaccine is made from the outer capsules of serogroup group A,C,W135 and Y Neisseria meningitidis organisms
  • meningococcal vaccine is a purified, heat stable, lyophilised extract from outer capsule of meningococcus serogroups A, C, Y and W135
  • in teenagers, both vaccines produce high levels of bactericidal antibodies to all four serogroups
  • response to MenC is good, regardless of the MenC vaccine received as a child
  • confers no protection against group B organisms
  • this vaccine is recommended for travellers to some countries

Check uptodate details in the The Green Book before prescribing/administering a quadrivalent (ACWY) polysaccharide vaccine.

Check the Summary of Product Characteristics (SPC) before prescribing/administering a quadrivalent (ACWY) polysaccharide vaccine.

Reference:

  1. Immunisation Against Infectious Disease - "The Green Book".Chapter 22 meningococcal (April 2019)

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.